Moderna and Merck’s Melanoma Vaccine Jumps Stocks on Phase 3 Win

Moderna (MRNA) and Merck (MRK) reported a major breakthrough on August 19 when their personalized mRNA cancer vaccine, intismeran autogene, succeeded in preventing melanoma recurrence in a large Phase 3 trial. The vaccine, combined with Merck’s immunotherapy drug Keytruda, reduced the risk of disease return or spread in patients with high-risk melanoma who had undergone surgery. MRNA jumped 8.9% to AUD $145.13 and MRK rose 2.4% to AUD $152.55, as the result validated mRNA technology as a viable cancer treatment and opened the door to vaccines for other tumor types.

How the vaccine works and what the trial showed

The vaccine trains the immune system to recognize mutations unique to each patient’s tumor. Doctors identified up to 34 neoantigens, or cancer fingerprints, from each patient’s tumor sample and encoded them into synthetic mRNA. Once administered, the body generates these proteins and teaches immune cells to attack them. In the KEYNOTE-942 trial involving over 1,000 high-risk melanoma patients, the vaccine combined with Keytruda succeeded in reducing the recurrence of melanoma when compared to Keytruda alone. Moderna expects thousands of melanoma patients could benefit within the first few years of approval.

Why this matters for cancer treatment

Unlike chemotherapy, which kills both healthy and cancerous cells, this vaccine specifically targets cancer mutations. Dr. Ryan Sullivan, director of the Center for Melanoma at Mass General Brigham Cancer Institute, called it a big deal for the field. Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology, said the result is a monumental leap forward. Sequencing companies including Illumina jumped 16% and Pacific Biosciences climbed 18% because personalized vaccines require tumor genetic testing.

Pipeline expansion beyond melanoma

Merck and Moderna have multiple trials under way for other cancers. Late-stage studies are testing the combination in non-small cell lung cancer, while mid-stage trials are running in bladder and kidney cancers. Early-stage trials have begun in pancreatic and stomach cancers. Moderna President Stephen Hoge told Reuters that numerous trial results are expected in the next year or two. Roche and BioNTech are also testing a similar treatment called autogene cevumeran in colon and pancreatic cancer studies.

Stock performance and investor outlook

MRNA rose 8.9% on the announcement to AUD $145.13, with RSI at 71.8 indicating overbought conditions. Meyka grades MRNA a B with a 12-month forecast of AUD $58.61, suggesting limited upside from current levels. MRK gained 2.4% to AUD $152.55 with RSI at 78.2, also overbought. Meyka grades MRK a B+ with a 12-month forecast of AUD $148.17, implying modest downside. Analyst consensus on both stocks is neutral to buy, but the data points to caution after such sharp moves.

Final Thoughts

The melanoma vaccine breakthrough validates mRNA technology and opens a multitrillion-dollar market for personalized cancer treatments. With both stocks overbought and Meyka forecasts below current prices, the initial rally may have priced in too much upside too soon.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.